Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16964
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPang, Jia-Min B-
dc.contributor.authorMolania, Ramyar-
dc.contributor.authorChand, Ashwini-
dc.contributor.authorKnower, Kevin-
dc.contributor.authorTakano, Elena A-
dc.contributor.authorByrne, David J-
dc.contributor.authorMikeska, Thomas-
dc.contributor.authorMillar, Ewan KA-
dc.contributor.authorLee, Cheok Soon-
dc.contributor.authorO’Toole, Sandra A-
dc.contributor.authorClyne, Colin-
dc.contributor.authorGorringe, Kylie L-
dc.contributor.authorDobrovic, Alexander-
dc.contributor.authorFox, Stephen B-
dc.date.accessioned2017-11-26T23:23:18Z-
dc.date.available2017-11-26T23:23:18Z-
dc.date.issued2017-07-28-
dc.identifier.citationOncotarget 2017; 8(48): 83626-83636en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16964-
dc.description.abstractThe significance and regulation of liver receptor homologue 1 (LRH-1, NR5A2), a tumour-promoting transcription factor in breast cancer cell lines, is unknown in clinical breast cancers. This study aims to determine LRH-1/NR5A2 expression in breast cancers and relationship with DNA methylation and tumour characteristics. In The Cancer Genome Atlas breast cancer cohort NR5A2 expression was positively associated with intragenic CpG island methylation (1.4-fold expression for fully methylated versus not fully methylated, p=0.01) and inversely associated with promoter CpG island methylation (0.6-fold expression for fully methylated versus not fully methylated, p=0.036). LRH-1 immunohistochemistry of 329 invasive carcinomas and ductal carcinoma in situ (DCIS) was performed. Densely punctate/coarsely granular nuclear reactivity was significantly associated with high tumour grade (p<0.005, p=0.033 in invasive carcinomas and DCIS respectively), negative estrogen receptor status (p=0.008, p=0.038 in overall cohort and invasive carcinomas, respectively), negative progesterone receptor status (p=0.003, p=0.013 in overall cohort and invasive carcinomas, respectively), HER2 amplification (overall cohort p=0.034) and non-luminal intrinsic subtype (p=0.018, p=0.038 in overall cohort and invasive carcinomas, respectively). These significant associations of LRH-1 protein expression with tumour phenotype suggest that LRH-1 is an important indicator of tumour biology in breast cancers and may be useful in risk stratification.en_US
dc.subjectDNA methylationen_US
dc.subjectNR5A2en_US
dc.subjectbreast carcinomaen_US
dc.subjectestrogen signallingen_US
dc.subjectimmunohistochemistryen_US
dc.titleLRH-1 expression patterns in breast cancer tissues are associated with tumour aggressivenessen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleOncotargeten_US
dc.identifier.pubmedurihttps://www.ncbi.nlm.nih.gov/pubmed/29137369en_US
dc.identifier.doi10.18632/oncotarget.18886en_US
dc.description.affiliatesDepartment of Pathology, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australiaen_US
dc.description.affiliatesTranslational Genomics & Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen_US
dc.description.affiliatesDepartment of Medicine, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.description.affiliatesCancer Drug Discovery Laboratory, Hudson Institute of Medical Research, Clayton, Victoria, Australiaen_US
dc.description.affiliatesSchool of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australiaen_US
dc.description.affiliatesDepartment of Pathology, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.description.affiliatesThe Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, NSW, Australiaen_US
dc.description.affiliatesSchool of Medical Sciences, University of New South Wales, Kensington, NSW, Australiaen_US
dc.description.affiliatesDiscipline of Pathology, School of Medicine, University of Western Sydney, Campbelltown, NSW, Australiaen_US
dc.description.affiliatesDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australiaen_US
dc.description.affiliatesCancer Pathology, Bosch Institute, University of Sydney, NSW, Australiaen_US
dc.description.affiliatesSydney Medical School, University of Sydney, NSW, Australiaen_US
dc.description.affiliatesCancer Genomics Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen_US
dc.description.affiliatesSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-3414-112Xen_US
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.